Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.
Daniel Fernandez-GarciaAllison HillsKaren PageRobert K HastingsBradley ToghillKate S GoddardCharlotte IonOlivia OgleAnna Rita BoydellKelly GleasonMark RutherfordAdrian LimDavid S GutteryR Charles CoombesJacqueline A ShawPublished in: Breast cancer research : BCR (2019)
Measurement of total cfDNA levels, which is a simpler and less expensive biomarker than CTC counts, is associated with PFS, OS and response in MBC, suggesting potential clinical application of a cheap and simple blood-based test.